White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

White paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

White paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

White paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

White paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

White paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

White paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

White paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

White paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

White paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

White paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

White paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

White paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

White paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

White paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

White paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

White paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

White paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

White paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

White paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

White paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

White paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

White paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

White paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

White paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

White paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

White paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

White paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

White paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

White paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

White paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

White paper

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

White paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

White paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

Let us help your business today.
Contact us now to start your journey.